Cargando…
Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form
Coronavirus disease -19 (COVID-19) pandemic, caused by SARS-CoV-2, has gradually spread worldwide, becoming a major public health event. This situation requires designing a novel antiviral agent against the SARS-CoV-2; however, this is time-consuming and the use of repurposed medicines may be promis...
Autores principales: | Tabarsi, Payam, Vahidi, Hossein, Saffaei, Ali, Hashemian, Seyed Mohammad Reza, Jammati, Hamidreza, Daraei, Bahram, Mahboubi, Arash, Kobarfard, Farzad, Marjani, Majid, Moniri, Afshin, Abtahian, Zahra, Abedini, Atefeh, Eslaminejad, Alireza, Heshmatnia, Jalal, Mirenayat, Maryam Sadat, Fakharian, Atefeh, Seifi, Sharareh, Sadeghi, Mohsen, Dastan, Alireza, Haseli, Sara, Nadji, Seyed Alireza, Eskandari, Raha, Yousefian, Sahar, Varahram, Mohammad, Zali, Alireza, Velayati, Ali Akbar, Dastan, Farzaneh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842610/ https://www.ncbi.nlm.nih.gov/pubmed/35194422 http://dx.doi.org/10.22037/ijpr.2021.115510.15401 |
Ejemplares similares
-
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2020) -
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial
por: Dastan, Farzaneh, et al.
Publicado: (2020) -
Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients
por: Baghaei, Parvaneh, et al.
Publicado: (2021) -
Clinical Manifestations of Patients with Coronavirus Disease 2019 (COVID-19) in a Referral Center in Iran
por: Baghaei, Parvaneh, et al.
Publicado: (2020) -
Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial
por: Barati, Saghar, et al.
Publicado: (2021)